Investment managers Sequoia Capital and GIC led a $760m funding round in TPG Asia-backed Novotech, a clinical research and testing provider. The funding will support Novotech to pursue further growth opportunities through M&A in geographical expansion as well as data, AI, and tech-enabled offerings. “We look forward to accelerating our growth by pursuing various strategic M&A and tech enablement initiatives and seek to better serve our biotech and pharmaceutical clients and support the clinical research industry in the development of a wide spectrum of therapeutic areas,” John Moller, Novotech CEO.